Daily non-political popular news in brief.

OCT1 required for therapeutic effects of diabetes drug Metformin

05-01-2007 · EurekAlert!

Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Mouse and human studies led by Kathleen Giacomini from the University of California, San Francisco, and reported in the May 1 issue of the JCI indicate that organic cation transporter 1 is important in mediating the therapeutic effects of metformin and that genetic variation in OCT1 in diabetics may contribute to the varied patient responses to this drug.

Keywords: oct1, required, therapeutic, effects, diabetes, drug, metformin, effect, diabete

« Previous | Next »

Similar news on "OCT1 required for therapeutic effects of diabetes drug Metformin":

JCI table of contents: May 1, 2007
05-01-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, May 1, 2007, in the JCI, including: "OCT1 required for therapeutic effects of diabetes drug Metformin"; "One genetic mutation heals another in blistering skin disease"; "Why wounds are slow to heal in diabetics"; "Researchers create 2 distinct mouse models of Omenn syndrome"; and "Deficiency in enzyme GGTase-I delays onset and severity of lung cancer in mice."
Similar news · Read more »
Carbon monoxide counteracts one side-effect of an anti-cancer drug
11-21-2007 · EurekAlert!
Doxorubicin (DOX) is a red-colored anti-cancer drug that carries serious side effects for the heart. These cardio-toxic effects are due to inhibition by DOX of mitochondrial biogenesis, a term used to describe cellular energy generation. In a new study, it is now shown that mitochondrial biogenesis can be recovered in DOX-treated rodents by either inhalation of carbon monoxide or overexpression of the protein HO-1.
Similar news · Read more »
Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs
01-08-2008 · EurekAlert!
Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the Jan. 9/16 issue of JAMA.
Similar news · Read more »
Stress triggers relapse in meth abuse, OHSU study finds
10-18-2006 · EurekAlert!
Oregon Health & Science University research showing stress triggers relapse of methamphetamine abuse in mice could be a step toward developing a drug to curb this frustrating obstacle to recovery. Results of the study not only validate earlier studies on the effects of stress on drug relapse in humans, they also show a compound researchers used to mimic metabolic changes that occur during stress creates a useful model for studying this effect in the laboratory.
Similar news · Read more »
Combination HDL/LDL therapy has no effect on plaque build-up
03-26-2007 · EurekAlert!
Two RADIANCE studies presented today at the American College of Cardiology's 56th Annual Scientific Session assessed the effects of adding torcetrapib to atorvastatin among patients to improve their cholesterol levels. Although the ILLUMINATE study and other trials involving torcetrapib were recently stopped because of safety concerns, the effect of the drug on carotid intima-media thickness (CIMT) may provide useful information on whether it slows the progression of atherosclerosis.
Similar news · Read more »
Annals of Internal Medicine tip sheet for April 3, 2007
04-02-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: New ACP Guideline for Mammography Screening Encourages Women 40 to 49 Years of Age to Become Part of the Decision-Making Process; Long-Term Effects of False-Positive Mammograms not Clear; New Injected Drug Added to Traditional Drug May Help Type 2 Diabetes; and Study Finds Kidney Dialysis Outcomes Vary by Race and Region.
Similar news · Read more »
Older is better -- Top-10 comparison of diabetes drugs give metformin top grade
07-24-2007 · EurekAlert!
Type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.
Similar news · Read more »
Drug could improve pregnancy outcomes in wider range of women with insulin resistance
09-06-2007 · EurekAlert!
Women who are obese, have type 2 diabetes or a family history of type 2 diabetes could one day have more successful pregnancies because of a study at Washington University School of Medicine in St. Louis. This study, performed in mice, suggests that Metformin, the most commonly prescribed anti-diabetes drug, could potentially improve pregnancy outcomes in women with insulin resistance.
Similar news · Read more »
Study: Re-engineered Gleevec reduces heart risks
12-03-2007 · EurekAlert!
Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib -- best known by its brand name Gleevec -- to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect. The re-design strategy employed in the study is broadly applicable to reducing side effects in other drugs.
Similar news · Read more »
Drug's potential adverse side effect explained
09-06-2007 · EurekAlert!
Drugs that are agonists of the receptor PPAR-gamma are used to treat individuals with diabetes. However, it has been suggested that their use is associated with a slightly increased risk of heart failure. A potential explanation for this adverse effect that is observed in a minority of patients is outlined in a new study in the Journal of Clinical Investigation.
Similar news · Read more »